← Leaderboards
Jeffrey Tornheim
Johns Hopkins University
$4,019,071
Attributed
$5,264,561
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,264,561 · 4
By mechanism
R01$4,200,681 · 2
K23$775,580 · 1
D43$288,300 · 1
Top collaborators
- Tony Y. Hu2 shared
- Robert H Gilman1 shared
- Zhen Huang1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Robert H Gilman$35,342,766
- Christopher B Umbricht$5,202,537
- Elizabeth A. Platz$18,230,919
- Alan Keith Meeker$5,318,574
- Patricia D. Hurn$12,295,669
Others in their field
Other Emerging Leaders on “Communicable Diseases”
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
- Kimberly Smith · Ppd Development Lp$71,100,376
- Beth Baseler · Leidos Biomedical Research, Inc.$67,833,289
- Bambra Strokes · Ppd Development Lp$65,000,267
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$53,368,527
- Sujatha Rashid · American Type Culture Collection$48,624,582
Research focus
Communicable DiseasesLaboratoriesBiomedical Referral CenterTuberculosis TreatmentDrug Resistance In TuberculosisDrug ResistanceSamplingPlasmaSputumTuberculosisCohortMultidrug-Resistant TuberculosisIndiaUnited States National Institutes Of HealthRifampicin ResistancePharmaceutical PreparationsPredispositionResistanceGenotypeFrequenciesAdultFuturePhenotypeMutation
Grant awards (12)
Multiplexed detection of cell-free M. Tuberculosis DNA and its drug-resistant variants in blood$722,477
R01 · FY2025 · AI
Baseline pRescription According to Direct from Sputum Sequencing and TArgeted drug Concentration Strategy (BRASS TACS)$364,801
R01 · FY2025 · AI · contact PI
Infectious Diseases Training program in Bolivia: South-South-North Training with Peru and JHU$288,300
D43 · FY2025 · TW
Baseline pRescription According to Direct from Sputum Sequencing and TArgeted drug Concentration Strategy (BRASS TACS)$287,459
R01 · FY2025 · AI · contact PI
Multiplexed detection of cell-free M. Tuberculosis DNA and its drug-resistant variants in blood$726,852
R01 · FY2024 · AI
Baseline pRescription According to Direct from Sputum Sequencing and TArgeted drug Concentration Strategy (BRASS TACS)$639,787
R01 · FY2024 · AI · contact PI
Multiplexed detection of cell-free M. Tuberculosis DNA and its drug-resistant variants in blood$753,352
R01 · FY2023 · AI
Baseline pRescription According to Direct from Sputum Sequencing and TArgeted drug Concentration Strategy (BRASS TACS)$705,953
R01 · FY2023 · AI · contact PI
Whole Genome Sequencing of Drug Resistant Tuberculosis in India: Genotype-Phenotype Correlation, Clinical Impact of Resistance, and Sequencing Directly from Sputum$194,213
K23 · FY2021 · AI · contact PI
Whole Genome Sequencing of Drug Resistant Tuberculosis in India: Genotype-Phenotype Correlation, Clinical Impact of Resistance, and Sequencing Directly from Sputum$193,789
K23 · FY2020 · AI · contact PI
Whole Genome Sequencing of Drug Resistant Tuberculosis in India: Genotype-Phenotype Correlation, Clinical Impact of Resistance, and Sequencing Directly from Sputum$193,789
K23 · FY2019 · AI · contact PI
Whole Genome Sequencing of Drug Resistant Tuberculosis in India: Genotype-Phenotype Correlation, Clinical Impact of Resistance, and Sequencing Directly from Sputum$193,789
K23 · FY2018 · AI · contact PI